An increased understanding of antitumor immunity is necessary for improving cell-based immunotherapies against human cancers. Here, we investigated the roles of two immune system-expressed microRNAs (miRNAs), miR-155 and miR-146a, in the regulation of antitumor immune responses. Our results indicate that miR-155 promotes and miR-146a inhibits interferon g (IFNg) responses by T cells and reduces solid tumor growth in vivo. Using a doubleknockout (DKO) mouse strain deficient in both miR-155 and miR-146a, we have also identified an epistatic relationship between these two miRNAs. DKO mice had defective T cell responses and tumor growth phenotypes similar to miR-155 À/À mice. Further analysis of the T cell compartment revealed that miR-155 modulates IFNg expression through a mechanism involving repression of Ship1. Our work reveals critical roles for miRNAs in the reciprocal regulation of CD4 + and CD8 + T cell-mediated antitumor immunity and demonstrates the dominant nature of miR-155 during its promotion of immune responses.
INTRODUCTION
Combating solid tumors remains an enormous challenge for the biomedical community. The need for improved therapies beyond radiation and chemotherapy has become evident, and there is growing interest in optimizing the use of immunotherapy as a treatment option. Among the cell types that hold promising therapeutic potential are T lymphocytes, including CD4 + interferon g (IFNg)-expressing Th1 cells and cytotoxic CD8 + T cells, which elicit tumor antigen-specific responses to direct the tumor microenvironment in a manner that restricts or eliminates tumor growth (Dougan and Dranoff, 2008; Dunn et al., 2004; Shiao et al., 2011) . However, there remain several aspects of antitumor immunity that are unclear and appear to be governed by complex regulatory systems that have limited this application in the clinic thus far (Zitvogel et al., 2006) . Therefore, an improved understanding of the molecular networks that influence T lymphocyte biology in the context of antitumor responses is needed, and this has the potential to improve our ability to manipulate this response in a manner that promotes tumor rejection.
Mammalian miRNAs have recently emerged as important regulators of immune cell development and function and represent a novel layer of control over cellular physiology (O'Connell et al., 2010c) . miRNAs are encoded by the genome and their transcription is regulated in a manner similar to other inflammatory protein coding genes, and this can involve such factors as nuclear factor kB (NF-kB) and AP-1 (O'Connell et al., 2007; Taganov et al., 2006; Thai et al., 2007) . Following their biogenesis, miRNAs are loaded into the RNA-induced silencing complex and guide this complex to the 3 0 UTRs of key target genes, resulting in repressed expression (Filipowicz et al., 2008) . In recent years, specific miRNAs have been shown to dramatically impact autoimmune and antimicrobial responses in mammals through their regulation of inflammatory T cells (Lu et al., 2009; O'Connell et al., 2010b; Rodriguez et al., 2007; Thai et al., 2007) .
One of the most prominent miRNAs linked to inflammation is miR-155, which is upregulated in both myeloid and lymphoid cells following their activation (Haasch et al., 2002; O'Connell et al., 2007) . In the T cell compartment, miR-155 regulates T regulatory cell fitness through a mechanism involving Socs1 repression (Lu et al., 2009) , while also being required for the development of inflammatory Th17 cells during autoimmunity driven by specific tissue antigens (Murugaiyan et al., 2011; O'Connell et al., 2010b) . miR-155 has been shown to be necessary for effective vaccination against S. typhimurium and immunity against H. pylori (Oertli et al., 2011; Rodriguez et al., 2007) . In contrast to miR-155, miR-146a limits T cell activation and promotes resolution of inflammatory responses. miR-146a À/À mice develop spontaneous autoimmunity and cancer upon aging, and this phenotype involves, among other things, hyperactivation of T cells via derepression of its targets Irak1 and Traf6 Yang et al., 2012; Zhao et al., 2011) . Stat1 has also been shown to be a functionally relevant target of miR-146a À/À in T regulatory cells (Lu et al., 2010) . Thus, these two miRNAs appear to have opposite impacts on inflammatory responses carried out by T lymphocytes in the contexts of autoimmunity and infection.
To date, little is known about the roles of T cell-expressed miR-155 and miR-146a during antitumor immune responses. To address this, we first tested the ability of miR-155 to mediate antitumor immunity using multiple models of syngeneic solid tumor growth in mice. We found that miR-155 À/À mice permit mice and monitored tumor growth over a time course. Although the tumor sizes were similar between the groups by day 9 postinjection, substantial differences in tumor diameters and weights were observed by day 12, with tumors growing much larger in miR-155 À/À versus WT mice ( Figures 1A and 1B ).
Because the tumor cells express luciferase, we also found that luciferase activity correlated with tumor size using Xenogen whole animal imaging ( Figures 1C and S1 ). Of note, we did not observe a luciferase signal from locations other than the site of tumor injection, suggesting that the tumor cells had not metastasized. (Ikeda et al., 2002; Jiang et al., 2011; Maekawa et al., 1988; Muranski et al., 2011; Yim et al., 1999) , we assayed the amount of CD4 + IFNg-expressing T cells in WT compared to miR-155 À/À tumor-bearing mice. In both the spleens and lymph nodes of mice with EL4-luc tumors, a lack of miR-155 led to significant reductions in both the percentage and absolute number of IFNg-producing CD4 + T cells compared to WT controls (Figures 2A, 2B , and S2). Of note, we only observed significant differences in the total number of IFNg+CD4+ splenic T cells in WT versus miR-155 À/À mice after administration of the tumor ( Figure 2C ). Further demonstrating a defective tumor immune response, we found that transfer of total splenocytes from WT, but not miR-155 À/À , tumor-bearing mice protected naive WT mice from a primary tumor challenge ( Figure S3 ). Next, we wanted to determine if this defective CD4 + T cell response was due to cell-intrinsic or cell-extrinsic pathways regulated by miR-155. To make this assessment, 4 3 10 6 naive 
miR-155 Plays a Dominant Role Compared to miR-146a during T Cell-Mediated Tumor Immunity
Like miR-155, miR-146a is also expressed in activated T cells. However, in contrast to miR-155, miR-146a À/À T cells have been reported to be hyperactivated during acute and chronic immune responses (Yang et al., 2012 ). Therefore, we tested whether miR-146a À/À mice have enhanced antitumor immunity compared to WT mice. miR-146a À/À , miR-155
, and WT mice were inoculated subcutaneously with 1 3 10 6 B16-F10 cells and tumor growth was monitored over a time course (Figure 4A) . Interestingly, tumors grew at a reduced rate in the absence of miR-146a compared to WT mice, while once again they grew larger in miR-155 À/À mice, suggesting that these miRNAs play opposing roles during antitumor responses. To examine the cross-regulation of tumor immunity by miR-155 and miR-146a, we created mice deficient in both miRNAs ( Figure 4B ). Using these mice, we assessed whether these opposing phenotypes would be canceled out, or if one of these two miRNAs plays a dominant role. DKO mice were viable and Figure 5A ). Alternatively, increased percentages of TILs were observed in tumors from miR-146a À/À compared to WT mice ( Figure 5A ). Figures 6C and 6D) . Importantly, levels To test the functional impact of elevated Ship1 expression (as observed in the absence of miR-155) on IFNg levels, we utilized small hairpin RNAs (shRNAs) to knock down Ship1 expression in activated WT, miR-155 À/À , miR-146a
, or DKO CD4 + T cells. We found that in T cells of all genotypes tested, reductions in Ship1 using either of two different shRNAs resulted in increased expression of IFNg mRNA compared to cells given a scrambled control vector ( Figure 6F ). Knockdown by the shRNA was confirmed by western blotting against Ship1 ( Figure 6G ). Expression of a Ship1 shRNA in activated CD4 + T cells also increased production of IFNg at the protein level as determined by ELISA ( Figure 6H) Figure 6I ). Taken together, these findings indicate that Ship1 is repressed by miR-155 in both CD4 + and CD8 + T cells. Furthermore, miR-155 promotes IFNg expression by CD4 + T cells through a mechanism involving repression of Ship1. However, the partial recovery of the IFNg phenotype following Ship1 knockdown indicates that addition targets of miR-155 are also involved in this phenotype.
DISCUSSION
MicroRNA-155 has quickly emerged as an important promoter of inflammatory responses, with a clear connection to autoimmunity. Furthermore, miR-155 is overexpressed in a variety of tumor cell types and can promote tumor growth in many cases (Bakirtzi et al., 2011; Chang et al., 2011; Han et al., 2012; Philippidou et al., 2010; Segura et al., 2010; Volinia et al., 2006; Zheng et al., 2012). Thus, it has been suggested that therapeutic inhibition of miR-155 may be a strategic means to treat autoimmunity or cancer. However, in the current study, we found that transferred syngeneic tumors grew substantially larger in mice genetically deficient in miR-155. Despite the tumors being weakly immunogenic, defects in the antitumor immune response were observed in the absence of miR-155, demonstrating a protective role for this miRNA in immune cells in the context of a tumor chal- There has been much consideration for using miR-155 as a biomarker of disease type and severity in human cancers where it is commonly overexpressed. Several instances of increased miR-155 levels correlating with more aggressive tumors with poor clinical outcomes have been reported (Chang et al., 2011; Han et al., 2012) . However, a recent study looking at human melanoma patients found that increased miR-155 expression correlated with an improved prognosis (Segura et al., 2010) . Although the study did not analyze distinct cellular subsets within the tumor, one could speculate that the increased miR-155 expression was a consequence of enhanced accumulation of immune cells within the tumor. Based upon our results here, it may prove valuable to carefully assess whether overexpression of miR-155 is occurring in tumor cells or in TILs that are actively fighting the tumor. This may give a more accurate assessment of whether increases in miR-155 are protective or deleterious.
Whereas miR-155 plays a host protective role against solid tumor growth, miR-146a appears to limit immunity against the same tumor type. We provide evidence that these contrasting roles are the consequence of reciprocal effects by these miRNAs on the tumor accumulation of IFNg expressing cells, including CD4 + and CD8 + T lymphocytes, which are critical mediators of antitumor immunity. These findings demonstrate that miRNAs in the immune system can play opposing roles in the regulation of a given phenotype. Thus, it is plausible that sets of miRNAs have evolved to provide balance to specific aspects of mammalian immunity, as has been proposed in stem cells (Melton et al., 2010 ). Consequently, we tested whether miR-155 and miR-146a function to provide immunological balance, or if one of these miRNAs has a dominant effect on IFNg + T cell formation and antitumor immunity. Using DKO mice, we determined that loss of miR-155 is largely epistatic to a deficiency in miR-146a in the contexts of IFNg + T cell formation and antitumor immunity. The enhanced antitumor response observed in miR-146a À/À mice was not only dependent upon miR-155 but was also worse than that observed in WT mice when miR-155 was also genetically absent. Therefore, our results indicate that miR-155 plays a dominant role, compared to miR-146a, in this context. Although studies carried out by our lab and others have provided evidence that these miRNAs oppose one another within T cells, it is probable that miR-155 and miR-146a impact antitumor immune responses by also acting in non-T cell types, such as macrophages, dendritic cells, and natural killer cells, where they have been shown to be expressed and to impact inflammatory responses Cubillos-Ruiz et al., 2012; O'Connell et al., 2007; Trotta et al., 2012) . Once conditional knockout mice are available for miR-155 and miR146a, studies can be carried out to specifically test the relative contributions of these miRNAs to the functions of distinct cell types that drive tumor immunity, and this will shed additional light on the cellular basis of the observed epistasis.
In an effort to unravel the molecular basis for miR-155's function in the T cell compartment, we found the miR-155 target Ship1 to be part of the connection between miR-155 and IFNg expression by CD4 + T cells. Ship1 is a phosphatase that negatively regulates cytokine signaling via repression of the PI3K pathway (Kerr, 2011) . A recent study looking at deletion of Ship1 specifically in CD4 + T cells using a CD4-CRE mouse strain with floxed Ship1 alleles found that Ship1 expression in T cells promotes IFNg expression by CD4 + T cells (Tarasenko et al., 2007) . Consistent with these observations, our Ship1 shRNA experiments found that defective expression of IFNg by miR-155 À/À CD4 + T cells could be partially complemented by reducing levels of Ship1, which are elevated in these cells. The same observations were made in DKO CD4 + T cells, indicating that Ship1 plays an increased inhibitory role when miR-155 is absent from either WT or normally hyperactive miR-146a
T cells. This effect of Ship1 provides at least part of the explanation for why miR-155 is dominant in the CD4 + T cell compartment. However, miR-155 is known to repress a variety of different mRNA targets, such as cMaf, PI3K p85, and Socs1, which could also influence IFNg responses by T cells. These proteins, in addition to Ship1, can act as inhibitors of IFNg or cellular activation in general Lu et al., 2009; Rodriguez et al., 2007) . Therefore, it is likely that miR-155 repression of this group of targets underlies its function in CD4 + T cells. In the case of CD8 + T cells, we also observed increased Ship1 expression in the absence of miR-155. Ship1 has been shown to inhibit CD8 + T cell cytotoxicity (Tarasenko et al., 2007) , suggesting that its regulation by miR-155 is also relevant in this cellular compartment. However, like CD4 + T cells, additional targets of miR-155 are also likely involved. There is increasing evidence that the crosstalk between the pathways regulated by miR-155 and miR-146a in T cells involves regulators of NF-kB activity, a transcription factor involved in IFNg transcription. miR-146a À/À T cells have just been shown to have increased activation of NF-kB following T cell receptor engagement as a result of derepression of its targets IRAK1 and TRAF6 (Yang et al., 2012) . This causes increased expression of IFNg by effector T cells deficient in miR-146a. Consequently, it is possible that the elevated levels of Ship1 ( Figure 5 ) and Socs1 (Lu et al., 2009 ) that are observed in miR-155 À/À T cells act to inhibit NF-kB activation, as they have been shown to do in other cell types (Gabhann et al., 2010; Serezani et al., 2011; Strebovsky et al., 2011) . This would negate the enhanced T cell activation observed in the absence of miR-146a alone. A careful dissection of these signaling pathways in the context of the different miRNA deficiencies will be an important future endeavor. Taken together, our study identifies a protective role for miR-155, and an inhibitory function for miR-146a, during antitumor immune responses, and argues for the importance of developing highly specific methods of modulating miRNAs when such approaches are used to combat cancer or autoimmunity. Additionally, by combining approaches that enhance miR-155 and/ or repress miR-146a levels in T lymphocytes with tumor vaccines or adoptive cell transfer therapies, one might achieve increased therapeutic efficacy in the clinic. Further studies will also be necessary to determine if miR-155 or miR-146a impact tumor metastasis in addition to modulating tumor growth. Finally, the importance of miR-155 in regulating IFNg + T cell responses during tumor immunity is highlighted by the finding that a miR-155 deficiency is epistatic to a loss of miR-146a in this cellular compartment.
EXPERIMENTAL PROCEDURES Mice
All mice were on a C57BL6 genetic background and housed in the animal facility at the University of Utah. Experiments were approved by the Rodriguez et al., 2007) . Xenogen live animal imaging to observe tumor expression of luciferase was performed as described (O'Connell et al., 2010a) . Irradiation was delivered using an X-ray source.
Tumor Challenges and Harvests
To create syngeneic subcutaneous tumors in mice, either EL4-luc lymphoma, B16-F10 melanoma, or B16-F1 melanoma cells were injected into the rear flanks of mice. The sites of tumor cell administration were shaved and cleaned before injection. Tumor growth was monitored over a time course by measuring tumor diameter. For analyses at the end of the time course, mice were euthanized and their tumors, spleens, and lymph nodes were removed and processed for FACS or histology. Following dissection, the tumors were weighed, minced into small pieces using a razor blade, and subsequently digested using Accumax. After the enzymatic digestion, the tumor cells were washed before further analysis. In some experiments, TILs were purified using FACS.
Adoptive Transfer of CD4 + and CD8 + T Cells
For T cell transfer experiments, CD4 + or CD8 + T cells were purified from naive mice (see below) and the indicated amounts of T cells were injected intravenously into recipient mice 1 day before tumor administration. In some experiments, recipients were first irradiated with 500 Rads using an X-ray source before receiving T cells. To distinguish between donor and recipient T cells, CD45.1 and CD45.2 congenic mouse strains were used when possible.
T Cell Isolation and Retroviral Infections
T cells were purified from red blood cell-lysed splenocytes using the MACS CD4 + or CD8 + T cell isolation kit (negative selection) from Miltenyi.
Purity was assessed by FACS and routinely reached 90%-95%. To create replication-deficient murine stem cell virus-based retroviral particles carrying the Ship1 or a scrambled control shRNA sequence, 293T cells were transfected with the MGP backbone and pCL-Eco packaging plasmids and retrovector-containing supernatant was recovered after 48 hr. The shRNA Ship1 expression vector has been described previously (O'Connell et al., 2009) . For retroviral transduction of CD4 + T cells, the cells were stimulated with aCD3 (3 mg/ml) and aCD28 (2 mg/ml) for 24 hr, subjected to a spin infection using retrovirus medium at 2,500 rpm at 30 C for 1.5 hr, then brought up in fresh activation medium for another 72 hr. Cellular infection was determined by microscopy or FACS to identify GFP + cells.
Intracellular Staining and FACS
Intracellular staining was performed as described previously (O'Connell et al., 2010b) . In short, 1 3 10 6 splenocytes, lymph node cells, or tumor suspension cells were restimulated with phorbol myristate acetate and ionomycin for 4 hr in the presence of Golgi Plug. Cells were next surface stained with aCD4 or aCD8 antibodies, washed, and permeabilized overnight using Perm Fix. After washing with Perm Buffer, the cells were stained using a phycoerythrin-conjugated mouse IFNg antibody. Following washing, cells were analyzed by FACS using a BD LSR Fortessa. For FACS sorting, cells were surface stained with aCD45 (pan), aCD3, and aCD4 or aCD8 fluorophore-conjugated antibodies, and cellular populations were sorted using a FACS Aria II in the Flow Cytometry Core Facility at the University of Utah. Other antibodies used for FACS include aCD45.1 and aCD45.2.
Western Blotting, ELISA, and qPCR Western blotting using cellular extracts from T lymphocytes was performed using standard protocols. Antibodies against mouse Ship1 and b-actin were obtained from Santa Cruz Biotechnology. For qPCR, RNA was extracted using the RNeasy or miRNeasy kits from QIAGEN per manufacturer's instructions. Following cDNA synthesis using total RNA, SYBRgreen-based qPCR was performed with gene-specific primers and the Roche Light Cycler 480. Primer sequences are available upon request. For detection of mature miRNAs 155 and 146a, or 5S ribosomal RNA, reagents and protocols from Exiqon were utilized. The ELISA assay used to quantify mouse IFNg concentrations was obtained from eBioscience and performed using the manufacturer's suggested protocol.
Histopathology
The tumors were dissected from the respective hosts and fixed with 10% formalin for at least 48 hr at room temperature. After fixation, the tumors were bisected across a maximum dimension and processed for paraffin embedding. Next, 5 mm-thick tissue sections were cut from paraffin blocks and stained with H&E per standard H&E protocol. The histopathological analysis was performed by a board-certified pathologist, and the images were taken using an Olympus BX41/DP72 microscope/camera. The magnification of the objective lens for each image is provided in the figures.
Statistical Analysis
A Student's t test was performed to determine statistical significance.
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